Tata India Pharma & Healthcare Growth Direct Plan
SIP amount
Min. ₹100
Lumpsum amount
Min. ₹5,000

Tata India Pharma & Healthcare Growth Direct Plan

NAV
₹29.2733
-0.58%
(24 May)
AUM
894 Cr
TER
0.83%
Risk
Very High Risk
Insights
Net Asset Value (NAV) is above its 200 days moving average
In beta. Send feedback here.
Compare with other fund
1Y
+110.2%
+110.0%
+104.2%
+88.5%
+56.6%
3Y
+41.8%
+42.6%
+43.7%
+40.2%
+17.3%
5Y
+26.5%
+31.8%
NA
+28.7%
+25.6%
ALL
+13.6%
+19.4%
+35.5%
+17.5%
+13.6%
VOL
19.9%
19.0%
21.8%
19.0%
15.7%
TER
0.9%
0.9%
0.5%
1.2%
0.8%
AUM
₹2,352 Cr
₹957 Cr
₹4,115 Cr
₹5,043 Cr
₹894 Cr
INFO
0.68
1.02
1.63
0.92
0.87
Past performance
Past performance is no guarantee of future returns.
Had you invested
Over the last
1Y
3Y
ALL
Your returns would have been
Tata India Pharma & Healthcare (G)
₹1,00,00,00,000
14.0%
Fixed deposit
₹40,00,00,000
6.0%
Bank savings
₹40,00,00,000
3.0%
See fund holdings as of 30th Apr
Top holdings
Sun Pharmaceuticals Industries Ltd
13.5%
Aurobindo Pharma Ltd
9.6%
Lupin Ltd
9.4%
Dr Reddy's Laboratories Ltd
7.5%
Cipla Ltd
6.5%
Zydus Lifesciences Ltd
5.0%
Divi's Laboratories Ltd
4.7%
Fortis Healthcare Ltd
4.2%
Apollo Hospitals Enterprise Ltd
3.9%
Alkem Laboratories Ltd
3.8%
Top industry exposure
Healthcare
95.7%
Basic Materials
2.0%
Other information
Minimum SIP
₹100
Minimum lumpsum
₹5,000
Additional lumpsum
₹1,000
Portfolio turnover
27%
Lock-in period
-
Exit load
• 0.25% for redemption within 30 days
Fund objective
The investment objective of the scheme is to seek long term capital appreciation by investing atleast 80% of its net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.However, there is no assurance or guarantee that the investment objective of the Scheme will be achieved.The Scheme does not assure or guarantee any returns.
Fund manager(s)
Meeta Shetty

FAQs